Consistent with previous studies, HOXD9 was significantly associated with prognosis of NAFLD patients in this analysis, indicating that HOXD9 may be an effective clinical therapeutic target for NAFLD of HCC with cirrhosis. Here, HOXD9 is linked to metabolic dysfunction-associated steatotic liver disease.